U.S. High Court Won’t Rule If Drug Maker Has Duty To Monitor Drug Study Patients
WASHINGTON, D.C. — The U.S. Supreme Court on Oct. 1 said it will not review a California state appeals court ruling that overturned a $5.6 million Risperdal death verdict, preserving a...To view the full article, register now.
Already a subscriber? Click here to view full article